23.70
-0.32 (-1.33%)
| Penutupan Terdahulu | 24.02 |
| Buka | 24.20 |
| Jumlah Dagangan | 1,486,000 |
| Purata Dagangan (3B) | 5,930,120 |
| Modal Pasaran | 33,378,031,616 |
| Harga / Pendapatan (P/E Ke hadapan) | 588.24 |
| Harga / Jualan (P/S) | 9.05 |
| Harga / Buku (P/B) | 3.43 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Oct 2025 |
| Margin Keuntungan | -59.61% |
| Margin Operasi (TTM) | -53.93% |
| EPS Cair (TTM) | -1.42 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 31.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 49.07% |
| Nisbah Semasa (MRQ) | 1.39 |
| Aliran Tunai Operasi (OCF TTM) | -1.08 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -261.82 M |
| Pulangan Atas Aset (ROA TTM) | -7.13% |
| Pulangan Atas Ekuiti (ROE TTM) | -21.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | JUNSHI BIO | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.25 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| JUNSHI BIO | 33 B | - | - | 3.43 |
| INNOVENT BIO | 161 B | - | 128.90 | 11.07 |
| WUXI BIO | 136 B | - | 30.50 | 2.72 |
| SINO BIOPHARM | 126 B | 1.15% | 29.38 | 3.35 |
| AKESO | 111 B | - | - | 15.36 |
| PHARMARON | 56 B | 0.92% | 22.04 | 2.34 |
|
Shanghai Junshi Biosciences Co Ltd is mainly engaged in innovation-driven biopharmaceutical business. The company's main products include teriprizumab injection, Etesevimab, adalimumab injection, and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases, and infectious diseases. The group’s operations are mainly located in the PRC and the United States of America. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Core |
| % Dimiliki oleh Orang Dalam | 19.28% |
| % Dimiliki oleh Institusi | 16.09% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |